Table 2.
Characteristics of the included RCT and cohort studies.
| Included studies | Country | Design | Sample size | Women, n (%) | Mean age | Follow-up | Traits of patients | Type of TIPS stents | Outcomes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | TIPS | BRTO | TIPS | BRTO | ||||||||
| Gimm et al. [27] | Korea | Cohort | 176 | 19 | 157 | 37 (21) | 59.4 | 54.4 | 5 years | GV bleeding | Covered | IM, RB, C, OS |
| Kim et al. [28] | Korea | Cohort | 52 | 27 | 25 | 24 (46) | 58.0 | 59.0 | 1 year | GV bleeding (isolated GV) | Covered | TS, C, MELD score, IM, RB, OS |
| Lee et al. [29] | Korea | Cohort | 142 | 47 | 95 | 27 (19) | 55.6 | 59.4 | 3 years | GV bleeding | Covered | TS, Child-Pugh, C, RB, IM, OS |
| Sabri et al. [30] | USA | Cohort | 50 | 27 | 23 | 21 (42) | 55.0 | 52.0 | 1 year▲ | GV bleeding (isolated GV) | Covered | TS, C, OS, RB, H |
| Lee et al. [24] | Korea | Cohort | 135 | 49 | 86 | — | 58.5 | 58.5 | 2 years | GV bleeding | — | RB, OS, C, |
| Sauk et al. [26] | USA | Cohort | 52 | 27 | 25 | 24 (46) | 58.0 | 59.0 | — | GV bleeding (isolated GV) | — | C, RB, |
| Lee et al. [25] | Korea | Cohort | 100 | 32 | 68 | — | — | — | — | GV bleeding | — | TS, RB, C, OS |
| Ninoi et al. [31]◆ | Japan | Cohort | 76 | 27 | 58 | 34 (58) | 58.7 | 60.3 | 5 years∗ | GV bleeding | Bare | TS, OS, Child-Pugh, C, RB, H |
| Choi et al. [33] | Korea | RCT | 14 | 7 | 7 | 4 (29) | 54.0 | 60.3 | 1 year■ | GV bleeding | Bare/covered | OS, Child-Pugh, C, RB, IM |
OS: overall survival; PSG: portosystemic gradient; GV: gastric variceal; IM: immediate haemostasis; RB: rebleeding; C: complications; TS: technical success; H:haemostasis. ◆Ninoi et al. compared TIPS with transcatheter sclerotherapy (including BRTO). We extracted relevant data about BRTO from the article. ▲The mean duration of follow-up was 19.5 months for patients in the TIPS group (range, 1–52 mo.) and 18.2 months for patients in the BRTO group (range, 1–49 mo.). ∗The follow-up period after the procedures was 41.2 ± 32.4 months in the TIPS group and 26.9 ± 16.5 months in the transcatheter sclerotherapy group (including BRTO). ■Patients were followed up for 6 to 21 (mean, 14.4) months. _Not mentioned.